Trial Profile
A Phase 2, Multicenter, Open-label, Single-Arm Study to Evaluate the Safety and Efficacy of Daratumumab in Combination with Ixazomib and Dexamethasone as Second Line Therapy in Multiple Myeloma Patients who have received prior treatment with a Lenalidomide based regimen
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Feb 2024
Price :
$35
*
At a glance
- Drugs Daratumumab (Primary) ; Daratumumab/hyaluronidase (Primary) ; Dexamethasone (Primary) ; Ixazomib (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms DARIA
- 15 Jun 2023 Final outcomes assessing the efficacy/safety of the Dara-Ixa-dex combination assecond-line therapy in pts with RRMM previously treated with a len-based regimen presented at the 28th Congress of the European Haematology Association.
- 05 Jun 2022 Status changed from recruiting to completed.
- 14 Dec 2021 Results assessing the efficacy of daratumumab in combination with ixazomib and dexamethasone (Dara-Ixa-dex) as second-line therapy in pts with RRMM who have been previously treated with a lenalidomide-based regimen, presented at the 63rd American Society of Hematology Annual Meeting and Exposition.